)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Medivir
Medivir (MVIR) investor relations material
Medivir Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 execution remained on plan: FLEX-HCC recruitment and MIV-711 proof-of-concept preparations advanced, alongside partnered programs.
Three capital raises totaled SEK 336m before transaction costs, funding three Phase II studies and operations at least into 2030; FLEX-HCC’s primary readout is expected in 2027.
Financial highlights
Q3 net turnover was SEK 0.7m vs SEK 0.9m YoY; total income was SEK 0.9m vs SEK 1.0m.
Q3 EBIT was SEK -17.1m vs SEK -13.6m, EBITDA SEK -15.9m vs SEK -12.9m, and net loss SEK 16.0m vs SEK 14.6m; higher clinical-study costs contributed to the wider operating loss.
9M net turnover was SEK 3.0m, unchanged YoY; EBIT was SEK -47.7m vs SEK -50.1m and net loss SEK 45.5m vs SEK 51.2m.
Operating cash outflow was SEK 14.7m in Q3 and SEK 46.1m in 9M; period-end cash was SEK 247.9m.
Q3 financing cash flow was SEK 9.2m, mainly from tranche two of the directed share issue; 9M financing cash flow was SEK 174.8m.
Outlook and guidance
FLEX-HCC enrollment is on plan at 12 South Korean sites, with all patients targeted for inclusion within 12 months of the May 2026 start and primary readout expected in 2027.
FLEX-HCC results are intended to inform pivotal study design, regulatory interactions and partnering; the next step is a randomized registrational study.
MIV-711 Phase II proof-of-concept preparations are progressing for osteogenesis imperfecta (OI) and Perthes disease; 2026/2027 priorities include site activation, study start-up and Perthes formulation completion.
Cash is assessed as sufficient at least into 2030 based on the current portfolio, excluding potential out-licensing proceeds, milestones and future partner revenues.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Medivir
- Fostrox plus lenvatinib showed early disease control in phase Ib HCC patients.MVIR
Study Update - MIV-818 showed liver delivery and extended stable disease in four HCC patients.MVIRStudy Result
- SEK 148m rights issue backs fostrox’s next HCC development steps.MVIRInvestor Update
- Three phase 2 studies fully funded, targeting high-value markets in liver cancer and rare bone diseases.MVIRCompany presentation
- SEK 140 million raised, three phase II studies funded, and positive fostrox clinical results.MVIRQ2 2026
- Fostrox + Lenvima delivers best-in-class efficacy for 2nd line HCC, targeting a $2.5bn+ market.MVIRDNB Nordic Healthcare Conference presentation
- Fostrox plus lenvatinib delivers superior efficacy and safety in second-line advanced liver cancer.MVIRPareto Securities Healthcare Conference presentation
- Fostrox + Lenvima shows promising efficacy in 2nd line HCC, targeting a major unmet need.MVIRCarnegie Småbolagsdag 2024
- Fostrox plus lenvatinib achieved 24% ORR in advanced HCC; randomized phase 2b is planned.MVIRStatus Update
Next Medivir earnings date
Q4 202618 Feb, 2027
Medivir
Next Medivir earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Medivir AB researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. It focuses on targeted therapies and vaccines. The company offers Merivo alfa, a product that has completed late stage clinical trials; MIV-711, which has completed phase I/II clinical trials; MIV-102 that has completed phase I/II clinical trial; and other projects in various phases of clinical development. Medivir AB was founded in 1987 and is headquartered in Huddinge, Sweden.